Objectives: The study aimed to describe patients with RRMM treated with carfilzomib (K), bortezomib (V), lenalidomide (R), pomalidomide (P), ixazomib (I), daratumumab (D) and elotuzumab (E). Methods: We analyzed 2017-18 data from crosssectional database Oncology Dynamics from Germany, France, UK, Italy and Spain by ongoing, mutually exclusive regimen and line (2 and 3L+). Line was defined by reporting physician. Treatment duration analysis included ongoing and completed regimens and was estimated with Kaplan-Meier method to account for censoring. Results: The study population of 2,654 RRMM patients included 75% of patients .65 years, .80% with ECOG 1-2, 32% had a transplant and mean estimated Charlson Comorbidity Index 5.4. Older patients received non-triplets more often. Patients in 2L were mostly treated with R non-triplet 49%, 20% V (including 10% non-triplet, 10% triplet), 15% K triplet regimens, 3-4% each with D, I, or E triplets, and 1-2% each with the rest of regimens. Frequencies differed by countries with D triplet more frequent in Germany and Spain. The most frequent previous treatment was V triplet 66% and non-triplet 15%; R was used in 4% of patients. 3L+ patients were treated with 23% D non-triplet, 25% P (5% triplet, 20% non-triplet), 18% K (10% triplet, 8% non-triplet), 12% R non-triplet, 9% V, and 1-2% each with the remaining regimens. 3L+ patients were pre-treated with R non-triplet 38%, 30% with V, 10% with P. Duration of treatment (in months) appeared similar for K triplets (median 17.0 [CI 16.3-18.8]) and D/E triplets 14.0 [CI 11.7-19.7]). For R/P non-triplets, median treatment duration was 18.0 (CI 16.5-20.2) and 9.4 (CI 8.3-10.9) for V/I/P triplets. Conclusions: Clinical characteristics of patients with RRMM were similar across regimens, with difference seen in age. Older, less intensive treatments were more frequently prescribed, which may be due to ongoing reimbursement discussions in some countries.